Phase 2 Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been newly diagnosed with acute myeloid leukaemia (AML) — meaning it was not caused by a previous cancer treatment or another blood disorder
- People aged 18 to 60 years old
- People whose AML has been classified as "low risk" according to a specific medical guideline called ELN2022
- People who have already completed 1 to 3 cycles of a high-dose chemotherapy treatment used after the main treatment phase
- People whose haemoglobin (a measure of red blood cells) falls within a specific range — between 60 and 90 g/L (confirm with trial site)
- People whose general physical functioning is rated at 2 or below on a standard medical scale called the ECOG scale, meaning they are able to care for themselves and are up and about for at least half of their waking hours
- People whose life expectancy is at least 3 months
- People who have read and signed a consent form and are willing and able to follow the study procedures
Who may not be able to join:
- People whose AML developed as a result of a previous cancer treatment or another blood condition (such as myelodysplastic syndrome)
- People who also have a bone marrow condition called myelofibrosis
- People whose anaemia does not improve with red blood cell transfusions
- People with heart function below a certain level (confirm with trial site)
- People with significantly reduced kidney function, specifically a creatinine clearance below 30 ml/min
- People with significantly reduced liver function, based on specific blood test results
- People with high blood pressure that remains difficult to control despite receiving treatment
- People who have had a stroke, a blood clot in a deep vein, or a blood clot in the lungs or arteries within the 6 months before joining the trial
- People with an active, uncontrolled infection (such as a fungal, bacterial, or viral infection that is not improving with treatment), or who have HIV, active hepatitis B, or hepatitis C
- People who have had a severe allergic reaction to similar medicines or to the specific study drug or its ingredients
- People who are pregnant or breastfeeding
- People considered unsuitable for the trial by the medical team overseeing the study
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +8615876559968
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Time of 50% increase in hemoglobin levels from baseline
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.